MoonLake Immunotherapeutics AG

Contributing Author

Recent Articles by MoonLake Immunotherapeutics AG

Nov-05	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering MLTX GlobeNewswire
Nov-05	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab MLTX GlobeNewswire
Sep-28	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab MLTX GlobeNewswire
Aug-05	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire
May-12	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire